Momenta Launches Study of Anticoagulant
Posted on: Tuesday, 16 October 2007, 12:00 CDT
Momenta Pharmaceuticals has treated the first patient in a multicenter Phase II study of its anticoagulant M118.
The Phase II study is designed to treat patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The company has also announced top-line results from a Phase I study in healthy volunteers designed to evaluate the human safety and pharmacokinetics of the intravenously administered anticoagulant, M118.
The primary objective of the Phase II trial is to evaluate the safety and feasibility of utilizing M118 as an anticoagulant during PCI. The multi-center study is expected to enroll approximately 600 patients with documented stable CAD who are planning to undergo a PCI.
Robert Harrington, professor of medicine at Duke University and director of the Duke clinical research institute, stated: "We're very interested in M118's potential. The data to date, both preclinical and Phase I, suggest that M118 may be able to improve upon current anticoagulant therapy in patients with acute coronary syndromes."
Source: Datamonitor
Related Articles
- Ablynx Announces Initiation of a Phase Ib Study in Patients for Alx-0081 and Provides a Business Update for the First Quarter 2008
- Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
- D-Pharm Announces the Second Recommendation of an Independent Safety Monitoring Board to Continue the Phase II Study of DP-B99 in Acute Stroke Patients
- Phase II Study Demonstrates That ONTAK(R) Benefits Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma
- ViroPharma Completes Enrollment in Phase 2 Clinical Study of Maribavir in Bone Marrow Transplant Patients
- D-Pharm Announces the Recommendation of an Independent Safety Monitoring Board to Continue the Phase II Study of DP-B99 in Acute Stroke Patients
- Preliminary Phase IIb Study Data Demonstrate Rylomine(TM) Significantly Reduces Postsurgical Orthopedic Pain
- Critical Therapeutics Announces Results From Phase II Study of Zileuton in Acne Patients
- AMEVIVE -- Alefacept -- Appears to Improve Patients' Psoriatic Arthritis in Phase II Study
- Results of Phase IIa Study Show That Reverset Has Potential to Reduce HIV Viral Load in Treatment-Experienced Patients
 |
 |
User Comments (0)
RSS Feeds